Doximity, Inc. Class A DOCS
NYSE · United States · Technology Services
$28.34+1.82 (+6.86%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Doximity (DOCS), which calls itself the leading digital platform for U.S. medical professionals, has seen its stock fall steeply over the past year. Even after a rise over the past three months, the shares sit about 65% below their 52-week high. Management continued its repurchase program, allocating approximately $401 million over the latest twelve months. The test is whether it can keep that up through what it calls its AI investment year.
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Doximity recently launched Bedside Bench, an open-source benchmark designed to evaluate clinical-grade AI using realistic bedside scenarios, and independent testing by Fireworks ranked its Doximity Ask system ahead of several frontier models. This move highlights how domain-specific, healthcare-focused AI can outperform general-purpose systems on clinically relevant tasks, potentially strengthening Doximity’s positioning as a trusted tool for physicians. We’ll now examine how Doximity’s...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.